Global Interstitial Lung Disease (ILD) Market Growth (Status and Outlook) 2025-2031

According to this study, the global Interstitial Lung Disease (ILD) market size will reach US$ million by 2031.

Interstitial Lung Disease (ILD), also referred to as pulmonary fibrosis or interstitial pneumonia, comprises a group of conditions characterized by varying degrees of inflammation and scarring around the tiny air sacs (alveoli) in the lungs. Interstitial Lung Disease treatment market in this report.

United States market for Interstitial Lung Disease (ILD) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Interstitial Lung Disease (ILD) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Interstitial Lung Disease (ILD) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Interstitial Lung Disease (ILD) players cover Boehringer Ingelheim, Bellerophon Therapeutics, Inc, Bayer, Fujirebio (Miraca), Philips, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Interstitial Lung Disease (ILD) Industry Forecast” looks at past sales and reviews total world Interstitial Lung Disease (ILD) sales in 2024, providing a comprehensive analysis by region and market sector of projected Interstitial Lung Disease (ILD) sales for 2025 through 2031. With Interstitial Lung Disease (ILD) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Interstitial Lung Disease (ILD) industry.

This Insight Report provides a comprehensive analysis of the global Interstitial Lung Disease (ILD) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Interstitial Lung Disease (ILD) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Interstitial Lung Disease (ILD) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Interstitial Lung Disease (ILD) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Interstitial Lung Disease (ILD).

This report presents a comprehensive overview, market shares, and growth opportunities of Interstitial Lung Disease (ILD) market by product type, application, key players and key regions and countries.

Segmentation by Type:
Interstitial Pneumonia
Idiopathic Pulmonary Fibrosis
Nonspecific Interstitial Pneumonitis
Hypersensitivity Pneumonitis
Cryptogenic Organizing Pneumonia
Acute Interstitial Pneumonitis
Desquamative Interstitial Pneumonitis
Others

Segmentation by Application:
Adults
Children

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Boehringer Ingelheim
Bellerophon Therapeutics, Inc
Bayer
Fujirebio (Miraca)
Philips
Merck
Siemens Healthineers

Please note: The report will take approximately 2 business days to prepare and deliver. Show more